Vaccibody Becomes Nykode Therapeutics - a New Name and Identity to Signify a New Phase of Growth and Development
Nykode Therapeutics (formerly Vaccibody*)) (Euronext Growth (Oslo): VACC (ticker will soon be changed)), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today that the Company is changing its name to reflect its exciting development and mark a milestone in our journey of growth and transformation. It acts as a visible symbol of a new phase of opportunity based on collaborations, internationalization, and future ambitions. And it conveys how we are truly starting to realize our vision of being a leading immunotherapy platform company, breaking down the boundaries of conventional drug design to unlock the future of medicine.
The Company’s new name is inspired by its Norwegian roots and links to our platform’s modularity. Nykode translates as ‘new code’, playing on the potential of our technology to generate novel codes and create innovative patient therapies.
Michael Engsig, CEO of Nykode Therapeutics: “Over the last few years, the Company has made significant steps forward. We have reported promising clinical data, continued to grow our pipeline and forged significant partnerships.” Michael Engsig added, “We continue our exciting transformation from a two-asset focused company to a fully-fledged platform biotech company. During the past year, we have increased the number of talented colleagues, made important additions to our senior management team, invested strategically, and expanded internationally. This positive evolution, combined with our future ambitions, inspired the need to revisit our brand.”
Agnete B. Fredriksen, Chief Innovation & Strategy Officer of Nykode Therapeutics, continued, “The challenge of changing our name was to consolidate everything we have achieved to date with our future plans to expand, and combine this into a powerful new brand.” Agnete B. Fredriksen added, “We have shown that we can generate novel molecules by combining multiple different genes or codes to generate new medicines with unique properties. We will build further on this know-how, driven by our guiding purpose to push the boundaries of human advancement by rethinking conventional drug design. We want to express how our platform’s intelligent modular design and tailored hyper targeting may deliver game-changing medicines for patients. This vision aims to create innovative therapies and continues to broaden our reach into multiple therapeutic areas, both with and without our partners. In essence, we believe that our new name, Nykode, uniquely captures our progress and possibilities.”
Read more about the journey and inspiration regarding our new name, logo, and visual identity on our new website, nykode.com.
*) Vaccibody AS, which is changing its company name to Nykode Therapeutics AS, has called for an EGM on November 30, 2021, to vote for the approval of the change of its company name from Vaccibody AS to Nykode Therapeutics AS.
About Nykode Therapeutics
Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and infectious diseases. Nykode Therapeutics’ modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.
Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumours and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.
The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and collaborate with Adaptive Biotechnologies for COVID-19 T cell vaccine development.
Nykode Therapeutics’ shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC (ticker will soon be changed). Further information about Nykode Therapeutics may be found at http://www.nykode.com
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact for Nykode Therapeutics AS:
CEO Michael Engsig
Nykode Therapeutics AS
Nykode Therapeutics AS
Oslo Science Park
N-0349 Oslo, Norway
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ITT’s Connector Business Introduces Veam MOVE-MOD™, Delivering True Modularity in Circular Interconnects30.11.2021 17:03:00 CET | Press release
November 30, 2021-- ITT Inc.’s (NYSE: ITT) connector business introduces its ruggedized, modular circular series Veam MOVE-MOD™. The flexible design delivers power, signal, and data in a single connector by utilizing a range of snap-in modules with various contact layouts to match individual system requirements. Developed for use in harsh environments, these ultra-durable connectors are suitable for a wide range of applications, including rail, heavy and off-road vehicles, alternative energy and infrastructure, robotics, and other industrial equipment. “Our customers have relied on Veam connectors to overcome their critical challenges for more than 60 years. MOVE-MOD is a next-generation solution designed to meet their evolving needs,” says Ellen McMillan, Vice President and General Manager Europe, ITT Connect and Control Technologies. “The modular nature of these innovative connectors give long-term flexibility to adapt, convert and expand connectivity post-design-in by simply swappin
Interactive Brokers Expands Tools for Global Investors30.11.2021 16:00:00 CET | Press release
Interactive Brokers Group (Nasdaq: IBKR), a global brokerage firm, today introduced GlobalAnalyst, a new tool that lets investors compare the relative valuations and financial metrics of stocks globally. GlobalAnalyst is designed for investors interested in international portfolio diversification to discover undervalued companies that may have greater growth potential. Recognizing that it can be challenging for investors to evaluate the relative merits of stocks traded in different currencies, Interactive Brokers created a simple yet powerful tool to compare any number of stocks by various metrics in one of 27 currencies of the user’s choice. Similarly, users may buy and sell and follow these stocks in the currency of their choice, all in one account on one screen. Using GlobalAnalyst, investors can search for stocks by region, country, industry, market capitalization and currency to identify undervalued stocks worldwide. A table displays current market and various financial metrics, s
New 7197PCP-DIN-NX Controller Improves Operational Efficiency by Allowing Centralized Control of Volumetric Dispensing Pumps30.11.2021 15:15:00 CET | Press release
Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces the 7197PCP-DIN-NX controller for 797PCP progressive cavity pumps. This controller provides Ethernet connection with Transmission Control Protocol / Internet Protocol (TCP/IP) for Smart Factory and Industry 4.0 manufacturing integration. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005031/en/ Improve operational efficiency by programming 797PCP volumetric dispensing pumps directly from a PLC via 7197PCP-DIN-NX controllers. (Photo: Business Wire) “This is enabling technology that allows our customers to be more lean, more efficient, more productive and more versatile as we prepare to enter fourth industrial revolution,” said Claude Bergeron, Senior Product Line Manager, Nordson EFD. “By helping manufacturers prepare, we ensure they won’t get left behind as Smart Factories transfer significant value to
AGCO Agriculture Foundation and MANRRS Announce a Three-Year Partnership to Advance Minority Representation in the Agricultural Industry30.11.2021 15:00:00 CET | Press release
The AGCO Agriculture Foundation (AAF), a private foundation committed to ending hunger through sustainable agricultural development, today announced a three-year partnership with Minorities in Agriculture, Natural Resources, and Related Sciences (MANRRS) to increase student representation from underrepresented backgrounds and to promote the agriculture industry as an admirable and sound career choice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005271/en/ AGCO Agriculture Foundation announces partnership with MANRRS (Graphic: Business Wire) Funded by the AAF, the project will provide scholarship opportunities for tailored internship roles and support for hiring talent from underrepresented groups. The focus areas will be agronomy, agribusiness, engineering, data science, software development, sustainability, field technicians, and related disciplines. The goal is to increase diversity and promote the agricultural in
Sekisui House, Ltd.: Working With Customers for 20 Years to Conserve Urban Biodiversity With the Gohon no ki Indigenous Landscaping Concept30.11.2021 15:00:00 CET | Press release
Sekisui House, Ltd. (TOKYO:1928) has been pursuing the conservation of biodiversity since 2001 by creating green networks in urban residential districts under its Gohon no ki (“five trees”) indigenous landscaping concept. Together with the University of the Ryukyus1, the company has analyzed the outcome of the Gohon no ki Project that it has implemented with 1 million customer households2 over the space of 20 years, and has designed the world’s first mechanism for quantitatively evaluating urban biodiversity. It has published this qualitative evaluation mechanism today as a nature-positive methodology for promoting the conservation of biodiversity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005350/en/ Results of quantitative evaluation analysis (1) - The number of native tree species in each region—the foundation of regional biodiversity—has increased tenfold. (Graphic: Business Wire) The Gohon no ki Project Since
CHG Healthcare Switches to Rimini Street to Achieve Better System Availability, Smoother Operation and Enhanced Outcomes for 25 Million Patients Annually30.11.2021 15:00:00 CET | Press release
Rimini Street, Inc. (NASDAQ: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that CHG Healthcare, the nation’s largest privately-held healthcare staffing company, has switched to Rimini Street support for its JD Edwards software. By switching support providers, CHG Healthcare now has an extension of its in-house IT team that includes Rimini Street’s expert, forward-thinking engineers who provide true, follow-the-sun, around the clock global support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005173/en/ CHG Healthcare Switches to Rimini Street to Achieve Better System Availability, Smoother Operation and Enhanced Outcomes for 25 Million Patients Annually (Photo: Business Wire) Assuring Medical Staff is Available to Serve Patients Headquartered in Midvale, Utah, CHG Healthcare
Shiji Selects Planview to Standardize its Project Portfolio Management Practices30.11.2021 15:00:00 CET | Press release
Planview, a global leader in Portfolio Management and Work Management solutions, today announced that Shiji, a leading multi-national technology company that provides software solutions and services for enterprise companies in the hospitality, food service, retail, and entertainment industries, has selected Planview Clarizen™ to standardize its project portfolio management (PPM) practices. This relationship will enable Shiji to engage with customers more effectively, driving customer success faster. Planview Clarizen creates a single point of entry for all projects, with a consistent and transparent view of progress, allowing Shiji’s executives to have the data they need for confidence in effective decision-making throughout the project lifecycle. Through this partnership, Shiji builds on its mission to provide a complete and modern technology stack for its customers, by selecting a modern PPM technology solution to assure that Shiji’s global services organization is scalable, secure,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom